Earnings Call Summary | Tracon Pharmaceuticals(TCON.US) Q1 2024 Earnings Conference
Earnings Call Summary | Tracon Pharmaceuticals(TCON.US) Q1 2024 Earnings Conference
The following is a summary of the TRACON Pharmaceuticals, Inc. (TCON) Q1 2024 Earnings Call Transcript:
以下是TRACON制药公司（TCON）2024年第一季度财报电话会议记录的摘要：
Financial Performance:
财务业绩：
TRACON's R&D expenses were down to $1.9 million in Q1 2024 from $5 million in Q1 2023 due to the termination of a pivotal trial.
General and administrative expenses decreased to $1.4 million from $2.3 million in Q1 2023 due to lower legal expenses.
Net loss was $3.2 million in Q1 2024, down from $8.5 million in Q1 2023.
$8 million in cash and cash equivalents held in March 2024.
由于一项关键试验的终止，TRACON的研发费用从2023年第一季度的500万美元降至2024年第一季度的190万美元。
由于法律费用减少，一般和管理费用从2023年第一季度的230万美元降至140万美元。
2024年第一季度的净亏损为320万美元，低于2023年第一季度的850万美元。
2024年3月持有的800万美元现金及现金等价物。
Business Progress:
业务进展：
Progress is sustained with the ongoing Phase II ENVASARC pivotal trial which is expected to conclude by Q3.
TRACON expects Fast Track designation for ENVA in certain sarcoma subtypes.
Development of clinical strategy for approval of ENVA in frontline sarcoma is ongoing.
An ongoing Phase II trial, sponsored by NCI, is assessing TRACON's DNA damage repair inhibitor TRC102 in Stage III non-small cell lung cancer.
The company licensed their PDP for $3 million upfront payment to a biotech company last year and plans on evaluating more drug candidates.
TRACON is considering options to meet NASDAQ's equity requirement by June 30, 2024.
正在进行的ENVASARC二期关键试验持续取得进展，该试验预计将于第三季度结束。
TRACON预计，某些肉瘤亚型中的ENVA被指定为快速通道。
批准ENVA用于一线肉瘤的临床策略正在制定中。
由NCI赞助的一项正在进行的二期试验正在评估TRACON在第三期非小细胞肺癌中的DNA损伤修复抑制剂 TRC102。
该公司去年以300万美元的预付款向一家生物技术公司许可了他们的PDP，并计划评估更多的候选药物。
TRACON正在考虑在2024年6月30日之前满足纳斯达克股票要求的期权。
More details: Tracon Pharmaceuticals IR
更多详情： Tracon 制药 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多详情，请访问投资者关系网站。本文仅供投资者参考，不构成任何投资建议。
译文内容由第三方软件翻译。